The Online Investor
OLI Premium
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
ChartZero
Arcutis Biotherapeutics Inc (ARQT)

Arcutis Biotherapeutics is a late-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with unmet medical needs. Co.'s product candidate, topical roflumilast cream, is used for plaque psoriasis, including intertriginous psoriasis, as well as atopic dermatitis. Co. is developing a topical foam formulation of roflumilast for the treatment of scalp psoriasis and seborrheic dermatitis; ARQ-252, a topical cream formulation of a small molecule inhibitor of Janus kinase type 1 for chronic hand eczema and vitiligo; and ARQ-255, an alternative topical formulation of ARQ-252 designed to reach into the skin in order to treat alopecia areata.

ARQT SEC Filing Email Alerts Service

Company Name:  Arcutis Biotherapeutics Inc
Website:  www.arcutis.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding ARQT:  23
Total Market Value Held by ETFs:  $96.16M
Total Market Capitalization:  $1.28B
% of Market Cap. Held by ETFs:  7.50%
August 13, 2022    12:19 PM Eastern


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Quotes delayed 20 minutes

Email EnvelopeFree ARQT Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Strong Buy (3.90 out of 4)
68th percentile
(ranked higher than approx. 68% of all stocks covered)

Analysts' Target Price:
ARQT Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Arcutis Biotherapeutics Inc (ARQT) Page | The Online Investor | www.TheOnlineInvestor.com | Copyright © 1998 - 2022, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.